Breast Cancer Vaccine Being Developed By Generex Subsidiary Antigen Express To Be Featured On Bloomberg Television Today

WORCESTER, Mass. and TORONTO, Dec. 19, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.  The segment is scheduled to air at 6 pm EST ( 3 pm PST) today, Monday, December 19, 2011 (see promo at http://i879.photobucket.com/albums/ab357/tc2000chartreader/72389a92.mp4.  It is expected that, once aired, the segment will be available for viewing on the Bloomberg website and on the Generex website.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

The story will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer.  The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations.

The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program.

Antigen Express has pioneered technology for increasing the potency of therapeutic anti-cancer vaccines.  Initial clinical studies showed that its lead compound, AE37, indeed showed surprisingly potent immunological activity without sacrificing any specificity in the immune response.  For the last four years, AE37 has been in a controlled, randomized Phase II study to determine whether it can indeed prevent recurrences in patients who have had breast cancer.  Positive interim results from that study were recently presented at the 34 ^th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  Final Phase 2 results are expected in 2012.

The Antigen Express AE37 breast cancer vaccine was also featured in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer?:( http://www.thedailybeast.com/newsweek/2011/12/11/could-this-be-the-end-of-cancer.html)." 

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

 

1 2 Next › Last »